Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 24

1.

Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression.

Farlow MR, Hake A, Messina J, Hartman R, Veach J, Anand R.

Arch Neurol. 2001 Mar;58(3):417-22.

PMID:
11255445
2.

Do cholinesterase inhibitors slow progression of Alzheimer's disease?

Farlow MR.

Int J Clin Pract Suppl. 2002 Jun;(127):37-44. Review.

PMID:
12139366
3.
4.

Rivastigmine for Alzheimer's disease.

Birks J, Grimley Evans J, Iakovidou V, Tsolaki M.

Cochrane Database Syst Rev. 2000;(4):CD001191. Review. Update in: Cochrane Database Syst Rev. 2009;(2):CD001191.

PMID:
11034705
5.

Reviews: Effects of transdermal rivastigmine on ADAS-cog items in mild-to-moderate Alzheimer's disease.

Grossberg GT, Schmitt FA, Meng X, Tekin S, Olin J.

Am J Alzheimers Dis Other Demen. 2010 Dec;25(8):627-33. doi: 10.1177/1533317510385808. Review.

PMID:
21131668
6.

Rivastigmine for Alzheimer's disease.

Birks J, Iakovidou V, Tsolaki M.

Cochrane Database Syst Rev. 2000;(2):CD001191. Review. Update in: Cochrane Database Syst Rev. 2000;(4):CD001191.

PMID:
10796621
7.
8.

Donepezil and rivastigmine in the treatment of Alzheimer's disease: a best-evidence synthesis of the published data on their efficacy and cost-effectiveness.

Wolfson C, Oremus M, Shukla V, Momoli F, Demers L, Perrault A, Moride Y.

Clin Ther. 2002 Jun;24(6):862-86; discussion 837. Review.

PMID:
12117079
9.

Safety and tolerability of transdermal and oral rivastigmine in Alzheimer's disease and Parkinson's disease dementia.

Darreh-Shori T, Jelic V.

Expert Opin Drug Saf. 2010 Jan;9(1):167-76. doi: 10.1517/14740330903439717. Review.

PMID:
20021294
11.

Rivastigmine transdermal system for the treatment of mild to moderate Alzheimer's disease.

Grossberg GT, Sadowsky C, Olin JT.

Int J Clin Pract. 2010 Apr;64(5):651-60. doi: 10.1111/j.1742-1241.2009.02330.x. Epub 2010 Jan 19. Review.

PMID:
20102418
12.

Pharmacokinetics of a novel transdermal rivastigmine patch for the treatment of Alzheimer's disease: a review.

Kurz A, Farlow M, Lefèvre G.

Int J Clin Pract. 2009 May;63(5):799-805. doi: 10.1111/j.1742-1241.2009.02052.x. Review.

13.

[Treatment of Alzheimer's disease: acetylcholinesterase inhibitors].

López-Pousa S, Lombardía Fernández C.

Neurologia. 1999 Apr;14(4):180-8. Review. Spanish.

PMID:
10363493
14.

Rivastigmine. A review of its use in Alzheimer's disease.

Spencer CM, Noble S.

Drugs Aging. 1998 Nov;13(5):391-411. Review.

PMID:
9829166
15.

Rivastigmine transdermal patch 13.3 mg/24 h: a review of its use in the management of mild to moderate Alzheimer's dementia.

Frampton JE.

Drugs Aging. 2014 Aug;31(8):639-49. doi: 10.1007/s40266-014-0197-x. Review.

PMID:
24989628
16.

Rivastigmine tartrate with a focus on dementia associated with Parkinson's disease.

Wesnes K.

Drugs Today (Barc). 2007 Jun;43(6):349-59. Review.

PMID:
17612707
17.

Long-term cholinesterase inhibitor treatment of Alzheimer's disease.

Johannsen P.

CNS Drugs. 2004;18(12):757-68. Review.

PMID:
15377166
18.

Potential savings in the cost of caring for Alzheimer's disease. Treatment with rivastigmine.

Hauber AB, Gnanasakthy A, Snyder EH, Bala MV, Richter A, Mauskopf JA.

Pharmacoeconomics. 2000 Apr;17(4):351-60. Review.

PMID:
10947490
19.

Statin therapy in Alzheimer's disease.

Sparks DL, Sabbagh M, Connor D, Soares H, Lopez J, Stankovic G, Johnson-Traver S, Ziolkowski C, Browne P.

Acta Neurol Scand Suppl. 2006;185:78-86. Review.

PMID:
16866915
20.

[Pharmacological profile and clinical results of the rivastigmine patch as a new therapeutic agent for Alzheimer's disease].

Fujii A, Shinagawa R, Chatani Y, Toriyama K, Shirahase T, Suzuki K.

Nihon Yakurigaku Zasshi. 2012 Jan;139(1):26-32. Review. Japanese. No abstract available.

PMID:
22230878

Supplemental Content

Support Center